InsidersTradesSigma
scPharmaceuticals Inc. Stock: price and insider trades · United States · SEC (Form 4)
Track the scPharmaceuticals Inc. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, scPharmaceuticals Inc. has recorded 30 reports. The latest transaction was filed on 7 October 2025 (U). Among the most active insiders: Nokes Rachael. Every trade is openly available.
30
Insider Decl.
0
Thresholds
€6m
4 ops.
Buy Volume
€4m
8 ops.
Sell Volume
29Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 7 October 2025
Declarations30 total
68,796 sharesCommon StockSEC:0001193125-25-233539:0
30,386 sharesCommon StockSEC:0001193125-25-233533:0
122,345 sharesCommon StockSEC:0001193125-25-233532:0
5,000 sharesCommon StockSEC:0001193125-25-233528:0
88,445 shares0Common StockSEC:0000950170-25-018879:0
200,000 shares0Common StockSEC:0000950170-25-018923:0
5,235 shares@ US$3.558731.1% of flowCommon StockSEC:0000950170-25-002868:0
13,360 shares@ US$3.55878.8% of flowCommon StockSEC:0000950170-25-002872:0
10,445 shares@ US$1.6627.2% of flowCommon StockSEC:0000950170-24-101430:0
5,223 shares@ US$1.66100.0% of flowCommon StockSEC:0000950170-24-101432:0
478,342 shares@ US$4.0031.2% of flowCommon StockSEC:0000947871-24-000701:0
Ideal exit: 10 May 2025 (T+270)
10,445 shares0Common StockSEC:0000950170-24-093994:0
113,560 shares0Common StockSEC:0000950170-24-006214:0
41,840 shares0Common StockSEC:0000950170-24-006215:0
1,027 shares@ US$6.3910.2% of flowCommon StockSEC:0000950170-24-001017:0
4,942 shares@ US$6.395.5% of flowCommon StockSEC:0000950170-24-000976:0
1,981 shares@ US$10.0931.6% of flowCommon StockSEC:0000899243-23-002425:0
66,665 shares@ US$6.1472.3% of flowCommon StockSEC:0000899243-23-002427:0
762,380 shares@ US$5.2568.8% of flowCommon StockSEC:0000947871-22-001214:0
Ideal exit: 22 Aug 2023 (T+270)
1,269 shares@ US$5.020.2% of flowCommon StockSEC:0001209191-22-053401:1
5,808 shares@ US$5.020.8% of flowCommon StockSEC:0001209191-22-053401:2
456,413 shares@ US$4.0952.0% of flowCommon StockSEC:0001209191-22-053401:3
19,017 shares@ US$4.092.2% of flowCommon StockSEC:0001209191-22-053401:4
87,036 shares@ US$4.099.9% of flowCommon StockSEC:0001209191-22-053401:5
30,457 shares@ US$5.024.2% of flowCommon StockSEC:0001209191-22-053401:0
25 of 30 declarations
About scPharmaceuticals Inc.
scPharmaceuticals Inc. is a United States biopharmaceutical company listed on the NASDAQ market in the United States, with headquarters in Burlington, Massachusetts. The company was formed in February 2013 in Delaware and has built its strategy around a highly specialized niche: converting therapies that are traditionally given intravenously into simpler, patient-friendly solutions that can be administered at home or in outpatient settings. Its business model is centered on drug-device combination products, with a clear focus on cardiorenal care. The company’s core commercial asset is FUROSCIX, a subcutaneous formulation of furosemide delivered through a wearable on-body infusor. FUROSCIX is designed to treat congestion due to fluid overload in adults with chronic heart failure, and in March 2025 the FDA approved an expanded indication for edema in patients with chronic kidney disease. That label expansion materially broadens the product’s commercial opportunity and supports the investment case around a large clinical need: reducing avoidable hospital visits and simplifying care delivery for patients with fluid-overload conditions. From a competitive standpoint, scPharmaceuticals differentiates itself as an early mover in the at-home subcutaneous delivery of loop diuretics. The company is addressing a market tied to heart failure, volume overload and broader cardiorenal management, where the value proposition is both clinical and economic. Its competitive edge comes from the convenience of the delivery system, the product’s technology differentiation, and its ability to fit into post-acute and chronic care pathways where payers and providers increasingly seek lower-cost alternatives to inpatient infusion. Over the past several quarters, management has focused on commercial execution for FUROSCIX and on regulatory expansion of the franchise. Recent milestones include FDA acceptance and subsequent approval of the CKD supplemental NDA, along with continued revenue growth in 2024 and early 2025. In 2025, the company also reported quarterly financial results and highlighted launch preparations for the new indication. For French-speaking investors, scPharmaceuticals represents a U.S. healthcare small cap with a concentrated risk profile, reliant on the commercial success of a single lead product and on disciplined execution across regulatory, medical and commercial fronts in the United States.
